GlobeNewswire Inc | Nov 18, 2021 09:45AM EST

November 18, 2021

Englewood Cliffs NJ, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that their joint venture partner Zylo Therapeutics received its first ketamine shipment and initiated loading ketamine into their Z-Pod transdermal technology.

Eric Weisblum, CEO of Silo Pharma statedThe commencement of Novel Ketamine loaded Z-Pods is a pivotal advancement for administering Ketamine as a therapeutic with the patented Z-Pod technology. This important milestone for Silo will help us study the benefits of slow-release transdermal release of Ketamine. The delivery and loading accelerates the developmentto deliver Ketamine as a therapeutic and potentially Psilocybin in a time-released or dosage-controlled manner.

About Silo PharmaSilo Pharma is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Alzheimers, Parkinsons, and other rare neurological disorders. Silos mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the health care industry. For more information, visitwww.silopharma.com.

Safe Harbor and Forward-Looking StatementsThis news release contains "forward-looking statements" within the meaning of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words could, believe, anticipate, intend, estimate, expect, may, continue, predict, potential and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (Silo or the Company) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Companys technology platforms, retaining and expanding the Companys customer base, fluctuations in consumer spending on the Companys products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events, or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.

Investor Relations Contact:Hayden IR Brett Maas646-536-7331 Email:brett@haydenir.com